Navigation Links
KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data
Date:8/6/2014

SAN FRANCISCO, Aug. 6, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the date for release of its 2014 second quarter financial results and provided the timeline for the release of topline data from its multi-center, pivotal clinical trial of CereKin™ for the treatment of osteoarthritis in dogs. The Company will release its 2014 second quarter financial results on August 13, 2014 after market close. The Company is on track to lock the database for the CereKin pivotal study in the first half of August and anticipates reporting the topline study data results during the week of August 18, 2014.

Conference Call and Webcast

The Company will host its 2014 second quarter earnings conference call at 4:30 p.m. Eastern Time on August 13, 2014.

Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 82174423.

The call will also be webcast live at http://www.media-server.com/m/p/ww4g9yvt. A replay will also be available at that link for 30 days.

About Kindred Biosciences

Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company's lead product candidates are CereKin™ (diacerein) for the treatment of osteoarthritis pain and inflammation
'/>"/>

SOURCE Kindred Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thoratec Schedules First Quarter Conference Call, Webcast
2. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
3. Heartware Schedules First Quarter Conference Call And Webcast
4. Ampio Pharmaceuticals Schedules 2012 Update Webcast
5. China Botanic Schedules Conference Call to Discuss Second Quarter Fiscal Year 2012 Results
6. Mylan Schedules Second Quarter 2012 Financial Results Conference Call and Live Webcast
7. Sinovac Schedules 2012 Annual Meeting of Shareholders
8. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
9. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
10. Thoratec Schedules Second Quarter Conference Call, Webcast
11. Bacterin International Holdings, Inc. Schedules Second Quarter 2012 Financial Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...   Cepheid (Nasdaq: CPHD ) today announced ... second quarter ended June 30, 2015 on Thursday, July ... The Company will host a management presentation at ... to discuss the results.  To access the live webcast, ... least 15 minutes before the scheduled start time to ...
(Date:7/6/2015)... , July 6, 2015 Akcea Therapeutics, ... ISIS ), announced today that the U.S. ... Designation to volanesorsen (ISIS-APOCIII Rx ) for the ... FCS is a rare genetic disease characterized by ... In a Phase 2 study published in the ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... DIEGO, Dec. 9 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... Brian M. Culley, will present to investors as part of ... 15, 2009 at 9:30 a.m. Eastern time. , Interested parties ... www.informedinvestors.com , a link to which is available on ...
... , WALTHAM, Mass., ... research and advisory firms focusing on pharmaceutical and healthcare issues, ... claims data, TNF-alpha inhibitors are being used more often to ... as many newly diagnosed second-line patients received a TNF-alpha inhibitor ...
Cached Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3
(Date:7/6/2015)... Georgia (PRWEB) , ... July 06, 2015 , ... ... has received nearly $400,000 in grant funds to support a three-year effort to ... , The work will be conducted in partnership with the Morehouse School of ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... Carlson finished his 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The operation took ... Newport News, VA. The procedure was an L5-S1 posterior lumbar interbody fusion on ...
(Date:7/5/2015)... (PRWEB) , ... July 06, 2015 , ... ... ancillary benefits market, is excited to announce the next generation of PrimeStar Individual ... Advantage plans to now include two network options—Maximum Allowable Charge (MAC) and usual, ...
(Date:7/5/2015)... ... ... Women’s Excellence in Wellness, powered by Movestrong is offering a student ... 2 months of unlimited classes for just $65. Student ID is needed at registration. ... Road in Lake Orion. , Women’s Excellence is the most comprehensive ...
(Date:7/4/2015)... ... , ... Chronic Neck Pain. Neck pain is no small problem. ... neck. Another 19% suffer from head, migraine, or facial pain, in some cases related ... American workers must deal with neck pain. Strategies for mitigating neck pain ...
Breaking Medicine News(10 mins):Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3
... A new study finds that people with prediabetes are no ... small fiber polyneuropathy than healthy people, a finding that contradicts ... said the results from their five-year study of 550 people ... in patients with painful small fiber polyneuropathy. Prediabetes, also ...
... , FRIDAY, Feb. 24 (HealthDay News) --,New ... predict age-related macular degeneration, one of the leading causes ... (AMD) were especially likely to have an overexpression of ... University of California Santa Barbara (UCSB), the University of ...
... in tumors., Invasion and metastasis were blocked by inhibition ... late-stage clinical trials. PHILADELPHIA Dual inhibition ... tumor invasion and metastasis in a laboratory model of ... Cancer Discovery , the newest journal of the ...
... Voluminous research literature attests to the multiple negative ... health and development of children. In contrast, there is ... fathers according to a follow up study by NYU ... edition of Maternal and Child Health Journal. ...
... features such as behavior, coat color and susceptibility to ... possible genetic cause for differential gene expression and biological ... pieces of mobile DNA that exist in the genome ... mice, according to a new study led by researchers ...
... , THURSDAY, Feb. 23 (HealthDay News) -- Noninvasive, ... its ability to detect colorectal cancer and precancerous polyps ... Virtual colonoscopy, also called CT colonography, uses virtual-reality ... and rectum. While preferred by many patients, its effectiveness ...
Cached Medicine News:Health News:Researchers Spot Genes Behind Macular Degeneration 2Health News:Combined inhibition of VEGF and c-MET can decrease metastasis 2Health News:Characteristics of fathers with depressive symptoms 2Health News:Characteristics of fathers with depressive symptoms 3Health News:Mobile DNA elements can disrupt gene expression and cause biological variation, study shows 2Health News:Study Supports CT-Based 'Virtual' Colonoscopy to Spot Colon Cancer 2Health News:Study Supports CT-Based 'Virtual' Colonoscopy to Spot Colon Cancer 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
Medicine Products: